412 related articles for article (PubMed ID: 33092403)
1. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase.
Xiao L; Salem JE; Clauss S; Hanley A; Bapat A; Hulsmans M; Iwamoto Y; Wojtkiewicz G; Cetinbas M; Schloss MJ; Tedeschi J; Lebrun-Vignes B; Lundby A; Sadreyev RI; Moslehi J; Nahrendorf M; Ellinor PT; Milan DJ
Circulation; 2020 Dec; 142(25):2443-2455. PubMed ID: 33092403
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium.
Jiang L; Li L; Ruan Y; Zuo S; Wu X; Zhao Q; Xing Y; Zhao X; Xia S; Bai R; Du X; Liu N; Ma CS
Heart Rhythm; 2019 Sep; 16(9):1374-1382. PubMed ID: 30959203
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death.
Boriani G; Menna P; Morgagni R; Minotti G; Vitolo M
Chemotherapy; 2023; 68(2):61-72. PubMed ID: 36366814
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.
Nicolson PLR; Hughes CE; Watson S; Nock SH; Hardy AT; Watson CN; Montague SJ; Clifford H; Huissoon AP; Malcor JD; Thomas MR; Pollitt AY; Tomlinson MG; Pratt G; Watson SP
Haematologica; 2018 Dec; 103(12):2097-2108. PubMed ID: 30026342
[TBL] [Abstract][Full Text] [Related]
5. Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis.
Tuomi JM; Bohne LJ; Dorey TW; Jansen HJ; Liu Y; Jones DL; Rose RA
J Am Heart Assoc; 2021 Nov; 10(22):e022369. PubMed ID: 34726066
[TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors.
Zhai Y; Hu F; Shi W; Ye X; Xu J; Guo X; Cao Y; He J; Xu F
Expert Opin Drug Saf; 2023; 22(9):857-869. PubMed ID: 37070462
[TBL] [Abstract][Full Text] [Related]
7. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.
Mato AR; Clasen S; Pickens P; Gashonia L; Rhodes J; Svoboda J; Hughes M; Nabhan C; Ali N; Schuster S; Carver J
Cancer Biol Ther; 2018 Jan; 19(1):1-2. PubMed ID: 29281559
[TBL] [Abstract][Full Text] [Related]
8. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Sestier M; Hillis C; Fraser G; Leong D
Curr Oncol Rep; 2021 Aug; 23(10):113. PubMed ID: 34342738
[TBL] [Abstract][Full Text] [Related]
9. Chronic B-Type Natriuretic Peptide Therapy Prevents Atrial Electrical Remodeling in a Rabbit Model of Atrial Fibrillation.
Zhao H; Li T; Liu G; Zhang L; Li G; Yu J; Lou Q; He R; Zhan C; Li L; Yang W; Zang Y; Cheng C; Li W
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):575-585. PubMed ID: 31159577
[TBL] [Abstract][Full Text] [Related]
10. Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation.
Yang X; An N; Zhong C; Guan M; Jiang Y; Li X; Zhang H; Wang L; Ruan Y; Gao Y; Liu N; Shang H; Xing Y
Redox Biol; 2020 Feb; 30():101432. PubMed ID: 31986467
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib's off-target mechanism: cause for dose optimization.
Zimmerman SM; Peer CJ; Figg WD
Cancer Biol Ther; 2021 Dec; 22(10-12):529-531. PubMed ID: 34632931
[TBL] [Abstract][Full Text] [Related]
12. HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice.
Scholz B; Schulte JS; Hamer S; Himmler K; Pluteanu F; Seidl MD; Stein J; Wardelmann E; Hammer E; Völker U; Müller FU
Circ Arrhythm Electrophysiol; 2019 Mar; 12(3):e007071. PubMed ID: 30879335
[TBL] [Abstract][Full Text] [Related]
13. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy.
Xiang S; Shen R; Xiang J; Zhu N; Gu J; Shen J; Zhang Y; Ge H
Expert Opin Drug Saf; 2024 May; 23(5):627-636. PubMed ID: 38456691
[TBL] [Abstract][Full Text] [Related]
14. NPR-C (Natriuretic Peptide Receptor-C) Modulates the Progression of Angiotensin II-Mediated Atrial Fibrillation and Atrial Remodeling in Mice.
Jansen HJ; Mackasey M; Moghtadaei M; Liu Y; Kaur J; Egom EE; Tuomi JM; Rafferty SA; Kirkby AW; Rose RA
Circ Arrhythm Electrophysiol; 2019 Jan; 12(1):e006863. PubMed ID: 30636477
[TBL] [Abstract][Full Text] [Related]
15. Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib.
Singh A; El Hangouche N; McGee K; Gong FF; Lentz R; Feinglass J; Akhter N
Echocardiography; 2021 Jan; 38(1):81-88. PubMed ID: 33594858
[TBL] [Abstract][Full Text] [Related]
16. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
Tang CPS; McMullen J; Tam C
Leuk Lymphoma; 2018 Jul; 59(7):1554-1564. PubMed ID: 28901789
[TBL] [Abstract][Full Text] [Related]
17. Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation.
Li LY; Lou Q; Liu GZ; Lv JC; Yun FX; Li TK; Yang W; Zhao HY; Zhang L; Bai N; Zhan CC; Yu J; Zang YX; Li WM
Eur J Pharmacol; 2020 Aug; 881():173120. PubMed ID: 32325147
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib-induced pulmonary angiotensin-converting enzyme activation promotes atrial fibrillation in rats.
Yan S; Xu W; Fang N; Li L; Yang N; Zhao X; Hao H; Zhang Y; Liang Q; Wang Z; Duan Y; Zhang S; Gong Y; Li Y
iScience; 2024 Feb; 27(2):108926. PubMed ID: 38357670
[TBL] [Abstract][Full Text] [Related]
19. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
20. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
